A systematic review of the effectiveness of adalimumab

134
References
148. Wolfe F, Michaud K. Lymphoma in rheumatoid
arthritis: the effect of methotrexate and anti-tumor
necrosis factor therapy in 18,572 patients. Arthritis
Rheum 2004;50:1740–51.
149. Baecklund E, Ekbom A, Sparen P, Feltelius N,
Klareskog L. Disease activity and risk of
lymphoma in patients with rheumatoid arthritis:
nested case–control study. BMJ 1998;317:
180–1.
150. Askling J, Fored CM, Baecklund E, Brandt L,
Backlin C, Ekbom A, et al. Haematopoietic
malignancies in rheumatoid arthritis: lymphoma
risk and characteristics after exposure to tumour
necrosis factor antagonists. Ann Rheum Dis 2005;
64:1414–20.
151. Geborek P, Bladstrom A, Turesson C, Gulfe A,
Petersson IF, Saxne T, et al. Tumour necrosis factor
blockers do not increase overall tumour risk in
patients with rheumatoid arthritis, but may be
associated with an increased risk of lymphomas.
Ann Rheum Dis 2005;64:699–703.
152. Askling J, Fored CM, Brandt L, Baecklund E,
Bertilsson L, Feltelius N, et al. Risks of solid
cancers in patients with rheumatoid arthritis and
after treatment with tumour necrosis factor
antagonists. Ann Rheum Dis 2005;64:1421–6.
153. Lebwohl M, Blum R, Berkowitz E, Kim D,
Zitnik R, Osteen C, et al. No evidence for
increased risk of cutaneous squamous cell
carcinoma in patients with rheumatoid arthritis
receiving etanercept for up to 5 years. Arch
Dermatol 2005;141:861–4.
154. Coletta AP, Clark AL, Banarjee P, Cleland JGF.
Clinical trials update: RENEWAL (RENAISSANCE
and RECOVER) and ATTACH. Eur J Heart Fail
2002;4:559–61.
155. Khanna D, McMahon M, Furst DE. Anti-tumor
necrosis factor therapy and heart failure. What
have we learned and where do we go from here?
Arthritis Rheum 2004;50:1040–50.
156. Chung ES, Packer M, Lo KH, Fasanmade AA,
Willerson JT. Randomized, double-blind, placebocontrolled,
pilot trial of infliximab, a chimeric
monoclonal antibody to tumor necrosis factor-, in
patients with moderate-to-severe heart failure:
results of the Anti-TNF Therapy Against
Congestive Heart failure (ATTACH) trial.
Circulation 2003;107:3133–40.
157. Genovese MC, Cohen S, Moreland L, Lium D,
Robbins S, Newmark R, et al. Combination therapy
with etanercept and anakinra in the treatment of
patients with rheumatoid arthritis who have been
treated unsuccessfully with methotrexate. Arthritis
Rheum 2004;50:1412–19.
158. Evers S, Goossens M, de Vet H, vanTulder M,
Ament A. Criteria list for assessment of
methodological quality of economic evaluations:
consensus on health economic criteria. Int J
Technol Assess Health Care 2005;21:240–5.
159. Choi HK, Seeger JD, Kuntz KM. A cost
effectiveness analysis of treatment options for
methotrexate-naïve rheumatoid arthritis.
J Rheumatol 2002;29:1156–65.
160. Brennan A, Bansback N, Reynolds A, Conway P.
Modelling the cost-effectiveness of etanercept in
adults with rheumatoid arthritis in the UK.
Rheumatology 2004;43:62–72.
161. Wong JB, Singh G, Kavanaugh A. Estimating the
cost-effectiveness of 54 weeks of infliximab for
rheumatoid arthritis. Am J Med 2002;113:400–8.
162. Kobelt G, Jonsson L, Young A, Eberhardt K. The
cost-effectiveness of infliximab (Remicade) in the
treatment of rheumatoid arthritis in Sweden and
the United Kingdom based on the ATTRACT
study. Rheumatology 2003;42:326–35.
163. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors
in the treatment of Rheumatoid Arthritis in
clinical practice: costs and outcomes in a follow up
study of patients with RA treated with etanercept
or infliximab in southern Sweden. Ann Rheum Dis
2004;63:4–10.
164. Chiou C-F, Choi J, Reyes CM. Cost-effectiveness
analysis of biological treatments for rheumatoid
arthritis. Expert Review of Pharmacoeconomics and
Outcomes Research 2004;4:307–15.
165. Welsing PMJ, Severens JL, Hartman M,
van Riel PLCM, Laan RFJM. Modeling the 5-year
cost effectiveness of treatment strategies including
tumor necrosis factor-blocking agents and
leflunomide for treating rheumatoid arthritis in
the Netherlands. Arthritis Rheum (Arthritis Care and
Research) 2004;51:964–73.
166. Bansback N, Brennan A, Ghatneker O. Cost
effectiveness of Adalimumab in the treatment of
moderate to severe rheumatoid arthritis patients
in Sweden. Ann Rheum Dis 2005;64:995–1002.
167. Kobelt G, Lindgren P, Singh A, Klareskog L.
Cost-effectiveness of etanercept (Enbrel) in
combination with methotrexate in the treatment of
active rheumatoid arthritis based on the TEMPO
trial. Ann Rheum Dis 2005;64:1174–9.
168. Brennan A, Bansback N. Re: Wolfe et al. Do
rheumatology cost-effectiveness analyses make
sense? Rheumatology 2004;43:677–8.
169. Wolfe F, Michaud K, Pincus T. Do rheumatology
cost-effectiveness analyses make sense?
Rheumatology 2004;43:4–6.
170. Chiou C, Choi J, Reyes CM. Cost-effectiveness
analysis of biological treatments for rheumatoid
arthritis. Review in Pharmacoeconomics Outcomes
Research 2004;4:307–15.